COVID-19 Vaccine Hesitancy among Adolescents: Cross-Sectional School Survey in Four Chinese Cities Prior to Vaccine Availability

Palizhati Rehati 1,†, Nubiya Amaerjiang 1,†, Liping Yang 1, Huidi Xiao 1, Menglong Li 1, Jiawulan Zunong 1, Long Wang 1, Sten H. Vermund 2 and Yifei Hu 1,*

1 Department of Child, Adolescent Health and Maternal Care, School of Public Health, Capital Medical University, Beijing 100069, China; plzt1998@163.com (P.R.); 1369367908163.com (N.A.); 13426838317@163.com (L.Y); xhd1998023@163.com (H.X.); liemenglong.ph@163.com (M.L.); jiawulanz@ccmu.edu.cn (J.Z.); wanglong201506@sina.com (L.W.)
2 Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT 06510-3201, USA; sten.vermund@yale.edu
* Correspondence: huyifei@yahoo.com or huyifei@ccmu.edu.cn; Tel./Fax: +86-10-8399-11747
† These authors contributed equally to this work.

Abstract: To address the novel coronavirus disease (COVID-19) pandemic, development and regulatory evaluations have been accelerated for vaccines, authorizing emergency use. To anticipate vaccine preparedness in adolescents, we studied COVID-19 vaccination awareness and willingness to vaccinate before the vaccine became available. We conducted a cross-sectional survey among 9153 (4575 boys, 50%) students with a mean age of 14.2 years old in four cities in China to collect information on demographic characteristics and their COVID-19 vaccination concerns. Multinomial logistic regression was used to analyze the influencing factors of vaccine hesitancy (“not sure”) and resistance (“do not want it”). The results showed that 2891 (31.6%) were hesitant and 765 (8.4%) were resistant to being vaccinated. Additionally, multivariable analyses showed that vaccine hesitancy and vaccine resistance were associated with living in the Beijing area (OR = 1.62; 95% CI: 1.40–1.88; OR = 1.81; 95% CI: 1.44–2.28), lack of influenza vaccination experience (OR = 1.33; 95% CI: 1.14–1.55; OR = 1.57; 95% CI: 1.25–1.98), no perceived susceptibility (OR = 1.72; 95% CI: 1.50–1.97; OR = 3.57; 95% CI: 2.86–4.46), and perceiving no cues to action (OR = 3.24; 95% CI: 2.56–4.11; OR = 27.68; 95% CI: 21.81–35.13). Postulating a highly effective vaccine (OR = 0.84; 95% CI: 0.72–0.98; OR = 0.66; 95% CI: 0.52–0.83) decreased both vaccine hesitancy and resistance. Vaccine hesitancy alone was associated with girls (OR = 1.21; 95% CI: 1.09–1.36) and was less common among students boarding at school (OR = 0.79; 95% CI: 0.68–0.92), postulating convenient vaccine access (OR = 0.84; 95% CI: 0.73–0.96), and having doctors’ recommendation (OR = 0.86; 95% CI: 0.76–0.98). In conclusion, the results of the study showed that vaccine hesitancy among students in China was associated with limited health literacy and lower risk awareness. Our findings in China suggest that educating youth regarding COVID-19 and the safety and effectiveness of immunization help reduce concerns and increase vaccine confidence and acceptance.

Keywords: vaccination; vaccine hesitancy; adolescents; willingness; COVID-19 vaccine

1. Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has had a devastating global disease burden since its outbreak, with a wide range of clinical presentations from asymptomatic to fulminant disease [1]. As of late February 2022, the cumulative number of confirmed cases of COVID-19 and deaths exceeded 430 million and 5 million worldwide, respectively. Over 10 billion doses of the vaccine have been administered but the fully vaccinated coverage was only 55% of the global population as of February 2022; therefore, vaccination and boost initiatives must continue [2].
Highly effective treatments to lower the morbidity and mortality of COVID-19 remain elusive [3]. In contrast, the vaccination has proven both effective and affordable, such that regulatory efforts have been accelerated to authorize earlier emergency use. Once a vaccination was developed which benefited adults and only caused serious adverse consequences on rare occasions, studies of youths ages 12 and up were completed, demonstrating safety and immunogenicity. As of February 2022, pediatric trials of COVID-19 vaccines in many countries have nearly been completed [4–6]. Along with the issues of efficacy and the delivery of the vaccine, it is important to monitor public confidence in immunization programs. Vaccine hesitancy is a major barrier to vaccine uptake and achievement of herd immunity, which is critical to protect the most vulnerable populations and contain the pandemic [7].

The social psychology of vaccine hesitancy suggests that education and socio-economic status do not influence hesitancy in only one direction, but rather can be associated with both lower and higher levels of vaccine acceptance in differing contexts [8]. To better understand the role of the multiple factors influencing the acceptance of vaccines, we adopted the health belief model as a theory-based research framework to assess vaccination intentions among adolescents [9–11]. The health belief model includes several components: perceived susceptibility, severity of the disease, vaccine benefits, vaccine risks, barriers to access, self-efficacy, and perceived cues to action [12]. Other salient issues can include demographic characteristics, understanding of vaccine effectiveness and safety, and convenience and the price of the vaccine [13]. Previous studies on the willingness to receive the COVID-19 vaccination included adults [14,15] and university students [16–18]. The few studies which investigated vaccine hesitancy in adolescents [19–21] mainly focused on the influence of parents on adolescents’ willingness to vaccinate, while studies among Chinese adolescents were mostly conducted in one city.

Since people of all ages are susceptible to SARS-CoV-2, and given the risk of transmission from children to vulnerable people, the society strategy for herd immunity must include a COVID-19 vaccine plan for children and adolescents. Students in China are the bridge population, connecting families to school gatherings, and vice versa; large gatherings can amplify SARS-CoV-2 transmission. An increase in vaccination rates among children and adolescents is crucial. At the time of our study (December 2021), vaccination was not recommended for adolescents or children due to a lack of phase III clinical data, including dosing for people under 18 years old. Additionally, China commenced a COVID-19 vaccination plan for children and adolescents aged 3 to 17 in July 2021 [22].

To our knowledge, no large-scale surveys of the COVID-19 vaccination of children and adolescents are being conducted preceding the immunization plan implemented in China. Additionally, we conducted a large cross-sectional study of vaccine hesitancy in four cities in eastern, southern, central and northwestern China to study a representative cross-section of the children and adolescents in China.

We aimed to investigate willingness to be vaccinated among Chinese children and adolescents and to assess possible factors of vaccine hesitancy and resistance in order to focus on children and adolescents in the current vaccination process to prepare for the expansion of immunization coverage in China.

2. Materials and Methods
2.1. Study Design

We conducted a cross-sectional survey on the willingness to receive COVID-19 vaccines among junior high (middle) school and senior high (upper) school students in four Chinese cities (Beijing, Xi’an in Shaanxi province, Shenzhen in Guangdong province, and Anqing in Anhui province) from 8 to 30 December 2020.

We used the Wenjuanxing® (Changsha Haoxing Information Technology Co. Ltd., Changsha, China) online survey tool (similar to SurveyMonkey®, San Mateo, CA, USA) for the informed consent process and administration of the online survey. We approached 9463 youth in grades 7–12 to answer the questionnaire, of whom 212 declined to participate.
(97.8% participation). After excluding invalid responses (inconsistent response across question options or plausibility of data ranges), 9153 questionnaires were finally included in the analysis. Figure 1 shows the participants’ recruitment and selection process.

Figure 1. Recruitment flowchart for the cross-sectional survey among school students in grades 7–12 in four cities in China.

Influenza immunization plans differed between Beijing and the other three cities, so we performed categorical analyses, comparing Beijing and the other cities for their demographic information. Schoolchildren in grades 7–12 were eligible in the four cities if they could read and comprehend the survey content and if they could independently complete the survey. We did not recruit adolescents from vocational schools.

We defined vaccine hesitancy as being unsure as to whether to accept the vaccination. Unwillingness to accept the vaccination was defined as vaccine resistance.

We calculated the sample size using the formula as

\[ n = \text{deff} \times \frac{Z^2_{\alpha/2}}{\delta^2} \times p (1 - p) \]

(\( n \) is the sample size, \( \text{deff} \) is the design effect, we assigned \( \text{deff} = 2.0 \) for cluster sampling, \( Z \) is distribution function for two-tailed alpha = 0.05, \( p \) is the targeted prevalence using influenza vaccination rates as a reference, and \( \delta \) is the acceptable standard error) [23] We chose \( p = 0.25 \) according to a meta-analysis of the influenza vaccination rate of people who were six months old to 17 years old from 2005 to 2017 estimates in China [24], assuming that the initial COVID-19 vaccination rates would be at least that of the influenza vaccination rate. With \( \delta = 0.1p \), we calculated the sample size as 2305 with 90% power to estimate the vaccine acceptance rate of the population. Assuming that 10–20% of participants might decline to participate in the survey, we planned a sample size of 2536–2767 respondents.
2.2. Measurement

The outcome variable was the willingness to receive the COVID-19 vaccination, once available, using the statement, “I am willing to get vaccinated”, and response options: “completely disagree”, “disagree”, “I don’t know”, “agree”, or “strongly agree”. For most analyses, we coded “completely disagree” and “disagree” into “resist to be vaccinated”, “I don’t know” as “hesitate to be vaccinated”, and merged “agree”, “strongly agree” into “willing”.

Covariates included sex, region, daily living, ethnicity, stage of schooling (junior (middle) or senior high (upper) school), and concerns about coronavirus and its vaccination, using statements such as, “I am afraid of coronavirus transmission”, “I have a risk of being infected by coronavirus”, and “the COVID-19 has made me pay more attention to the influence of infectious diseases in my life, influencing me to get/want an influenza vaccine”. We assessed the major concerns that youth report would affect vaccination decisions, including vaccine safety, effectiveness, price, convenience, and doctors’ recommendation. We included two items to explore a possible association of experiences of the influenza vaccination and attitudes towards the COVID-19 vaccination: “Have you been vaccinated for influenza this year?” and “I had a positive experience with my influenza vaccination”.

The health belief model (HBM) is a common tool to evaluate vaccine hesitancy. Based on available HBM questionnaires and scales [25–28], we developed the questionnaire to include sociodemographic characteristics. Briefly, HBM is comprised of six domains: perceived risk (perceived severity and perceived susceptibility, 2 items), perceived benefits and barriers (4 items) and cues to action (2 items), self-efficacy (2 items), demographic characteristics (5 items), and knowledge (1 item) (Figure 2).

2.3. Statistical Analysis

Participants’ characteristics were described using frequencies and percentages. Influencing factors of acceptance of a COVID-19 vaccine were assessed with Chi-square test, including variables with two-sided \( p \leq 0.05 \) in multinomial logistic regression, presented
with odds ratios (OR) and 95% confidence intervals (CI). All data were analyzed using Statistical Analysis System software (V.9.4, SAS Institute Inc., Cary, NC, USA).

3. Results

A total of 9153 respondents—ages ranging from 12.0 to 17.5 years, with an average age of 14.2 (SD = 1.6)—were finally included in the analysis.

3.1. Demographic Characteristics of the Participants

Among 9153 respondents, 765 (8.4%) were not willing to get vaccinated (resistant), 2891 (31.6%) were not sure about the vaccination, and 5497 (60.0%) were willing to receive a COVID-19 vaccine (Table 1).

Table 1. Demographic characteristics and COVID-19 vaccination concerns of school students in grades 7–12 in four cities in China (N = 9153).

| Demographic Characteristics                                      | n (%)  |
|------------------------------------------------------------------|--------|
| Sex                                                              |        |
| Boy                                                              | 4575 (50.0) |
| Girl                                                             | 4578 (50.0) |
| Daily living                                                     |        |
| Boarding at school                                               | 1822 (19.9) |
| Not boarding                                                     | 7331 (80.1) |
| Ethnicity                                                        |        |
| Han                                                               | 8618 (94.2) |
| Minorities                                                       | 535 (5.8) |
| Stage of schooling                                               |        |
| Junior high (middle) school grades 7–9                           | 5708 (62.4) |
| Senior high (upper) school grades 10–12                          | 3445 (37.6) |
| Region                                                           |        |
| Beijing                                                          | 5000 (54.6) |
| Anqing, Anhui province                                           | 278 (3.0) |
| Shenzhen, Guangdong province                                     | 1308 (14.3) |
| Xi’an, Shaanxi province                                          | 2567 (28.1) |
| COVID-19 concerns                                                |        |
| I am afraid of SARS-CoV-2 transmission                           |        |
| Agree                                                            | 7248 (79.2) |
| Not sure                                                         | 852 (9.3) |
| Disagree                                                         | 1053 (11.5) |
| I have a potential risk of being infected with SARS-CoV-2        |        |
| Agree                                                            | 3550 (38.8) |
| Not sure                                                         | 2536 (27.7) |
| Disagree                                                         | 3067 (33.5) |
| The COVID-19 has made me pay more attention to the influence of infectious diseases in my life, influencing me to get/want an influenza vaccine |        |
| Agree                                                            | 6412 (70.0) |
| Not sure                                                         | 2059 (22.5) |
| Disagree                                                         | 682 (7.5)  |
| COVID-19 vaccination concerns                                    |        |
| I will get the COVID-19 vaccine                                  |        |
| Agree                                                            | 5497 (60.0) |
| Not sure                                                         | 2891 (31.6) |
| Disagree                                                         | 765 (8.4)  |
| Major concerns that affect my COVID-19 vaccination decision       |        |
| Safety                                                           | 8516 (93.0) |
| Effectiveness                                                    | 7587 (82.9) |
| Price                                                            | 3520 (38.5) |
| Convenience                                                      | 3448 (37.7) |
| Doctors’ recommendation                                          | 3116 (34.0) |
Table 1. Cont.

| Demographic Characteristics |  
|-----------------------------|
| **Influenza vaccination**    |  
| Did you get influenza vaccination in 2020 |  
| Yes | 3494 (38.2) |
| No | 5659 (61.8) |
| I have experience with a prior influenza vaccination |  
| Agree | 5240 (57.2) |
| Not sure | 1992 (21.8) |
| Disagree | 1921 (21.0) |

Note: The statement, "Major concerns that affect my COVID-19 vaccination decision", has multiple responses, including safety, effectiveness, price, convenience, and a doctor’s recommendation.

3.2. Comparison of Vaccination Willingness

There was no difference between Han and ethnic minority youth in willingness to receive the vaccination ($p = 0.84$). In contrast, differences in vaccine hesitancy were noted by sex, daily living, stage of schooling, region, and perceptions of COVID-19 vaccination (Table 2).

Table 2. Demographic characteristics and COVID-19 vaccination concerns of school students in grades 7–12 in four cities in China, by willingness to getting the vaccine (N = 9153).

| Characteristics | Resist to Be Vaccinated (N = 765), n (%) | Hesitate to Be Vaccinated (N = 2891), n (%) | Willing to Be Vaccinated (N = 5497), n (%) | p |
|-----------------|----------------------------------------|----------------------------------------|----------------------------------------|---|
| **Demographic characteristics** |  
| **Sex** | <0.001 |
| Boy | 392 (8.6) |
| Girl | 373 (8.1) |
| **Daily living** | 0.015 |
| Boarding at school | 137 (7.5) |
| Not boarding | 628 (8.6) |
| **Ethnicity** | 0.836 |
| Han | 722 (8.4) |
| Minorities | 43 (8.0) |
| **Stage of schooling** | 0.012 |
| Junior high (middle) school grades 7–9 | 512 (9.0) |
| Senior high (upper) school grades 10–12 | 253 (7.3) |
| **Region** | <0.001 |
| Beijing | 481 (9.6) |
| Anqing, Anhui province | 14 (5.0) |
| Shenzhen, Guangdong province | 63 (4.8) |
| Xi’an, Shaanxi province | 207 (8.1) |
| **COVID-19 concerns** | <0.001 |
| I am afraid of SARS-CoV-2 transmission |  
| Agree | 507 (7.0) |
| Not sure | 39 (4.6) |
| Disagree | 219 (20.8) |
| I have a potential risk of being infected with SARS-CoV-2 |  
| Agree | 166 (4.7) |
| Not sure | 117 (4.6) |
| Disagree | 482 (15.7) |
| The COVID-19 has made me pay more attention to the influence of infectious diseases in my life, influencing me to get an influenza vaccine | <0.001 |
| Agree | 245 (3.8) |
| Not sure | 158 (7.7) |
| Disagree | 362 (53.1) |
### Table 2. Cont.

| Characteristics | Resist to Be Vaccinated (N = 765), n (%) | Hesitate to Be Vaccinated (N = 2891), n (%) | Willing to Be Vaccinated (N = 5497), n (%) | p          |
|-----------------|----------------------------------------|---------------------------------------------|--------------------------------------------|------------|
| COVID-19 vaccination concerns |                                        |                                             |                                            |            |
| Major concerns that affect my COVID-19 vaccination decision |                                        |                                             |                                            | <0.001     |
| Safety          | 680 (8.0)                              | 2667 (31.3)                                | 5169 (60.7)                                |            |
| Effectiveness   | 571 (7.5)                              | 2326 (30.7)                                | 4690 (61.8)                                |            |
| Price           | 213 (6.1)                              | 1100 (31.3)                                | 2207 (62.7)                                |            |
| Convenience     | 208 (6.0)                              | 999 (29.0)                                 | 2241 (65.0)                                |            |
| Doctors’ recommendation | 209 (6.7) | 908 (29.1) | 1999 (64.2) |            |
| Influenza vaccination |                                        |                                             |                                            |            |
| Did you get influenza vaccination in 2020 |                                        |                                             |                                            | <0.001     |
| Yes             | 242 (6.9)                              | 972 (27.8)                                 | 2280 (65.3)                                |            |
| No              | 523 (9.2)                              | 1919 (33.9)                                | 3217 (56.8)                                |            |
| I have experience with a prior influenza vaccination |                                        |                                             |                                            | <0.001     |
| Agree           | 353 (6.7)                              | 1336 (25.5)                                | 3551 (67.8)                                |            |
| Not sure        | 143 (7.2)                              | 890 (44.7)                                 | 959 (48.1)                                 |            |
| Disagree        | 269 (14.0)                             | 665 (34.6)                                 | 987 (51.4)                                 |            |

3.3. Factors Influencing Vaccine Resistance

The likelihood ratio of multinomial logistic regression was 4288.2 (DF = 40, N = 9153, \( p < 0.001 \)), and the values of Cox and Snell \( R^2 \), and Nagelkerke \( R^2 \) were 37.4% and 45.2%, respectively. The results showed that Xi’an students were more likely than the Beijing referent group to desire a COVID-19 vaccine (OR = 1.81; 95% CI: 1.44–2.28). Adolescents with no experience with the influenza vaccine (OR = 1.57; 95% CI: 1.25–1.98) or who were unsure about having it (OR = 1.30; 95% CI: 1.01–1.67) were more resistant to the COVID-19 vaccination (Table 3). The more effective the COVID-19 vaccine was believed to be, the less resistant students were to vaccinate (OR = 0.66; 95% CI: 0.52–0.83). Students who were not afraid of SARS-CoV-2 transmission were more vaccine-resistant (OR = 1.35; 95% CI: 1.07–1.71). Students who did not perceive that they were susceptible to COVID-19 (OR = 3.57; 95% CI: 2.86–4.46) or were unsure about the risk of infection (OR = 1.43; 95% CI: 1.08–1.89) were more vaccine-resistant. Students who thought that COVID-19 would have no impact on their lives (OR = 27.68; 95% CI: 21.81–35.13) or those who were not aware of any impact (OR = 8.03; 95% CI: 6.30–10.22) were more vaccine-resistant. No association of vaccine resistance was noted by sex, stage of schooling, daily living, receiving an influenza vaccine in 2020, concerns about a vaccine’s safety, price, convenience, or doctors’ recommendation (Table 3).

Table 3. Factors associated with the willingness of receiving a COVID-19 vaccine among school students in grades 7–12 in four cities in China—multinomial logistic regression.

| Factors                        | Intend to Be Vaccinated: Vaccine Resistance vs. Willing | p   | Intend to Be Vaccinated: Vaccine Hesitancy vs. Willing | p   |
|--------------------------------|--------------------------------------------------------|-----|--------------------------------------------------------|-----|
|                                | OR (95% CI)                                            |     | OR (95% CI)                                            |     |
| Sex                            |                                                        |     |                                                        |     |
| Boy                            | Ref                                                    | 0.692|                                                        |     |
| Girl                           | 1.04 (0.87–1.24)                                        |     | 1.21 (1.09–1.36)                                       | <0.001|
| Daily living                   |                                                        |     |                                                        |     |
| Boarding at school             | 0.78 (0.61–1.00)                                        | 0.052| 0.79 (0.68–0.92)                                       | 0.003|
| Not boarding                   | Ref                                                    |     | Ref                                                    |     |
Table 3. Cont.

| Factors                                      | Intend to Be Vaccinated: Vaccine Resistance vs. Willing | Intend to Be Vaccinated: Vaccine Hesitancy vs. Willing |
|----------------------------------------------|--------------------------------------------------------|-------------------------------------------------------|
|                                              | OR (95% CI) p                                         | OR (95% CI) p                                         |
| Stage of schooling                           |                                                        |                                                        |
| Junior high (middle) school grades 7–9       | 0.99 (0.80–1.22) 0.913                                | 0.98 (0.86–1.11) 0.725                                |
| Senior high (upper) school grades 10–12      | Ref                                                    | Ref                                                   |
| Region                                       |                                                        |                                                        |
| Beijing                                      | 1.81 (1.44–2.28) <0.001                                | 1.62 (1.40–1.88) <0.001                                |
| Anqing, Anhui province                       | 0.65 (0.34–1.25) 0.200                                 | 1.23 (0.89–1.71) 0.213                                 |
| Shenzhen, Guangdong province                 | 0.72 (0.51–1.01) 0.056                                 | 0.90 (0.75–1.09) 0.282                                 |
| Xi’an, Shaanxi province                      | Ref                                                    | Ref                                                   |
| I am afraid of SARS-CoV-2 transmission       |                                                        |                                                        |
| Agree                                        | Ref                                                    | Ref                                                   |
| Not sure                                     | 0.87 (0.58–1.29) 0.487                                 | 2.09 (1.70–2.57) <0.001                                |
| Disagree                                     | 1.35 (1.07–1.71) 0.013                                 | 0.93 (0.78–1.12) 0.458                                 |
| I have a potential risk of being infected with SARS-CoV-2 |                                                        |                                                        |
| Agree                                        | Ref                                                    | Ref                                                   |
| Not sure                                     | 1.43 (1.08–1.89) 0.012                                 | 1.93 (1.67–2.22) <0.001                                |
| Disagree                                     | 3.57 (2.86–4.46) <0.001                                | 1.72 (1.50–1.97) <0.001                                |
| The COVID-19 has made me pay more attention to the influence of infectious diseases in my life, influencing me to get an influenza vaccine |                                                        |                                                        |
| Agree                                        | Ref                                                    | Ref                                                   |
| Not sure                                     | 8.03 (6.30–10.22) <0.001                               | 14.15 (12.27–16.31) <0.001                            |
| Disagree                                     | 27.68 (21.81–35.13) <0.001                             | 3.24 (2.56–4.11) <0.001                               |
| Major concerns that affect my vaccination    |                                                        |                                                        |
| Safety                                       | 0.80 (0.58–1.10) 0.167                                 | 1.20 (0.95–1.50) 0.130                                 |
| Effectiveness                                | 0.66 (0.52–0.83) <0.001                                | 0.84 (0.72–0.98) 0.027                                 |
| Price                                        | 0.86 (0.69–1.07) 0.169                                 | 1.20 (1.05–1.36) 0.007                                 |
| Convenience                                  | 0.81 (0.64–1.01) 0.064                                 | 0.84 (0.73–0.96) 0.011                                 |
| Doctors’ recommendation                      | 0.93 (0.75–1.15) 0.496                                 | 0.86 (0.76–0.98) 0.025                                 |
| Did you get influenza vaccination in 2020    |                                                        |                                                        |
| Yes                                          | 0.88 (0.72–1.09) 0.240                                 | 0.89 (0.78–1.01) 0.063                                 |
| No                                           | Ref                                                    | Ref                                                   |
| I have experience with a prior influenza vaccination |                                                        |                                                        |
| Agree                                        | Ref                                                    | Ref                                                   |
| Not sure                                     | 1.30 (1.01–1.67) 0.038                                 | 1.44 (1.24–1.67) <0.001                                |
| Disagree                                     | 1.57 (1.25–1.98) <0.001                                | 1.33 (1.14–1.55) <0.001                                |

3.4. Factors Influencing Vaccine Hesitancy

Compared with boys, girls were more likely to be vaccine-hesitant (OR = 1.21; 95% CI: 1.09–1.36). The relative odds of vaccine hesitancy among students in Beijing were 1.62 times higher (OR = 1.62; 95% CI: 1.40–1.88) than that of school students in Xi’an. The odds of vaccine hesitancy among boarding students were 21% lower (OR = 0.79; 95% CI: 0.68–0.92) than non-boarders. Participants who had no experience with an influenza vaccine (OR = 1.33; 95% CI: 1.14–1.55) or were not sure about their experience (OR = 1.44; 95% CI: 1.24–1.67) were more likely to hesitate. The more effective the vaccine is believed, the less hesitant were the students to vaccinate (OR = 0.84; 95% CI: 0.72–0.98). Higher COVID-19 vaccine price concerns increased hesitancy (OR = 1.20; 95% CI: 1.05–1.36). Anticipated convenience to vaccinate reduced vaccine hesitancy (OR = 0.84; 95% CI: 0.73–0.96), as did doctors’ recommendation to vaccinate (OR = 0.86; 95% CI: 0.76–0.98). Students who did not know much about SARS-CoV-2 were more likely to be hesitant (OR = 2.09; 95% CI: 1.70–2.57), as were respondents who believed that COVID-19 would have little or no influence in their lives (OR = 3.24; 95% CI: 2.56–4.11) or were not concerned about COVID-19 (OR = 14.15; 95% CI: 12.27–16.31). Stage of schooling and having received an influenza vaccine in 2020 were not associated with COVID-19 vaccination hesitancy (Table 3).
4. Discussion

Our survey suggested that only 60% of school students in grades 7–12 wanted to receive a COVID-19 vaccine in China prior to the vaccine being available for them, in contrast to the much higher willingness indicated among Chinese adults during the active SARS-CoV-2 transmission period in Wuhan [15]. The students with concerns included 31.6% who were hesitant and 8.4% who were resistant to receiving a COVID-19 vaccine. Our findings were similar to other nations: in countries such as Sweden, Canada, the US, and England, around 30–40% of adolescents would hesitate to accept a COVID-19 vaccination [20,29–31].

There was a sex discrepancy between vaccine hesitancy, with girls less willing to receive a COVID-19 vaccine, consistent with previous studies [32–34]. We speculate that this may be due to misinformation circulating on social media about the COVID-19 vaccine reducing fertility, but further research will be needed to confirm this. Boarding students were more willing to be vaccinated; we speculate that they may be more influenced by teachers than by their parents, given findings that parental vaccine hesitancy, refusals, delays, and negative attitudes may influence adolescent vaccine hesitancy or deferral [35].

We were surprised that students in Beijing were less willing to be vaccinated, but this may also be parentally influenced. In the Tongzhou District of Beijing, only about 60% of parents chose to vaccinate themselves and their children; this is lower than their willingness to receive influenza or HPV vaccines [36]. In contrast, 79.2% of residents living in Guangzhou were willing to be vaccinated [37].

Students who have been vaccinated against influenza were more willing to receive a COVID-19 vaccine. Knowledge of influenza immunization benefits are relevant to the awareness of similar advantages in preventing COVID-19 and other respiratory viral infections [38]. Experience with the influenza vaccination was reported to be associated with higher COVID-19 vaccine acceptance [39]. The promulgation of the influenza vaccination may increase the possibility of Chinese adults to accept the COVID-19 vaccination [40], and our findings suggest that influenza vaccine efforts may also work to scale-up COVID-19 vaccination willingness among students.

Vaccine hesitancy has been suggested as one of the top 10 threats to global health in 2019 [41]. We found that vaccine hesitancy was associated with a low awareness of SARS-CoV-2, while vaccine resistance was associated with a lower perceived severity of COVID-19 [19]. Self-perception of being at a high risk of developing a serious COVID-19 infection has become a positive predictor of future vaccination [42]. HBM theory supports the premise that education about the content in advance, addressing of prior symptoms or concerns, and receiving the correct information from the mass media are cues which can influence behavior and help to prevent COVID-19 via an increase in vaccination uptake. We found that students who did not realize the magnitude of the COVID-19 pandemic’s impact were more likely to be resistant or hesitant to a vaccine. According to a WHO/UNICEF joint report using 2015–2017 data, the principal reasons for vaccine hesitancy were a lack of knowledge and awareness of vaccination and a lack of understanding of its importance [43]. In addition, people who are vaccine-resistant have been exposed to significantly less information about COVID-19 from the public media compared to those willing to receive a vaccine [32].

In our study, students overwhelmingly cited the safety (93.0%) and effectiveness (82.9%) of a vaccine as major considerations affecting their decision. Vaccine hesitancy was related to concerns about vaccine effectiveness, lower perceived convenience, higher price, and lack of doctors’ recommendation. According to China’s current vaccine immunization plan, all people eligible for a COVID-19 vaccine will receive it for free, so this is information that must be conveyed to youth. Vaccination inconvenience hinders people from promptly vaccinating, a remediable challenge [40].

Vaccine safety is essential to “first do no harm” and to maintain public trust in vaccines. Each COVID-19 vaccine must be demonstrated to be safe for adolescents and then for younger children at appropriate doses, at which time the authorization from regulatory
agencies will be broadened as per the data-based evidence. COVID-19 vaccines are likely to be even more effective and safe than other childhood vaccines [44]. High COVID-19 vaccine effectiveness and safety are playing a pivotal role in chipping away at vaccine hesitancy over time [45]. Vaccine hesitancy was initially related to public perceptions of ineffective vaccines and safety concerns [46]. We found that, in Chinese youth, doctors’ recommendation may decrease vaccine hesitancy [40]. People who are vaccine-resistant report lower levels of trust in information released by their doctors, other health care professionals, and/or government agencies [32]. It is plausible that excellent, consistent, persistent, and effective public communications can help improve vaccination uptake regardless of the setting and causes of vaccine hesitancy [8].

Our study’s strengths include our provision of baseline information for continuously monitoring teenagers’ acceptance of the COVID-19 vaccine in China. Given what we discovered to be the major concerns of young people, a blueprint for education is suggested for adolescents. Our four cities provide geographical diversity throughout China, improving the generalizability potential of our findings. We acknowledge several limitations of our study. First, though the 9153 students represent a considerable overall sample, a study limitation includes the low representation of students in Anqing City. A second limitation is that recall bias can be influential in a cross-sectional survey, such as with remembering one’s influenza vaccine experience—though forgetting about an injection is presumably less common in teenagers than for younger children. Third, we did not investigate vaccine hesitancy across different types of COVID-19 vaccines and the psychology of vaccine hesitancy and resistant individuals (such as personality, altruism, or domains from mental health scales, such as Revised Children’s Anxiety and Depression Scales (RCADS)) to further understand the reason for vaccine hesitancy. In addition, misinformation can lead to hesitancy.

As of February 2022, over 3 billion doses of the COVID-19 vaccine have been administered, according to the report of National Health Commission of the People’s Republic of China [47]. Our study provides an early glance into the willingness and potential hesitancy to receive of a COVID-19 vaccine among students in grades 7–12 in urban China. With the current deployment of vaccines to teenagers, these data can help with baseline information to monitor changes in vaccine acceptability among adolescents. Our results highlight that vaccine hesitancy is associated with a limited understanding of SARS-CoV-2 transmission dynamics and insufficient risk awareness [48,49]. We recommend that schools, community leaders, health care providers, governments, and parents improve information, education, and communication of the comparative benefits of a COVID-19 vaccine among adolescents.

5. Conclusions

In conclusion, vaccine hesitancy in Chinese adolescents was associated with limited health literacy and lower risk perception. More youth-friendly messages regarding COVID-19, as well as the safety and effectiveness of the immunization against misinformation, may help address vaccine hesitancy. Our findings can inform public health campaigns to boost the immunization rate.

Author Contributions: Y.H. conceptualized and designed the study. N.A., L.Y., H.X., M.L., J.Z. and L.W. conducted the survey; P.R. performed data analysis and drafted the original manuscript. N.A. checked the data analysis process; S.H.V. and Y.H. helped interpret and revise the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Natural Science Foundation of China (Y.H., grant No. 72061137007; Y.H., grant No. 81673232; Y.H., grant No. 82073574) and the National Institutes of Health grant (S.H.V., grant No. P30MH062294). The sponsors had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Institutional Review Board Statement: The study was approved by Capital Medical University Ethics Review Board (Z2020SY116).
Informed Consent Statement: All participants provided online informed consent.

Data Availability Statement: The data that support the findings of this study are not publicly available but are available from the corresponding author on reasonable request.

Acknowledgments: We thank Xiaoyan Wu, Ruiilan Zhao, Songjie Zhang, Jian Sun, and Shaojun Xu for local coordination of the survey. We express our sincere gratitude to the participants for their time and participation. We would like to send thanks to the peer reviewers for their constructive and insightful comments.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Wiersinga, W.J.; Rhodes, A.; Cheng, A.C.; Peacock, S.J.; Prescott, H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020, 324, 782–793. [CrossRef] [PubMed]
2. Sun, Y. Shaping Hong Kong cinema’s new icon: Milkyway Image at international film festivals. Transnatl. Cine. 2015, 6, 67–83. [CrossRef] [PubMed]
3. Asselah, T.; Durantel, D.; Pasmant, E.; Lau, G.; Schinazi, R.F. COVID-19: Discovery, diagnostics and drug development. J. Hepatol. 2021, 74, 168–184. [CrossRef] [PubMed]
4. Han, B.; Song, Y.; Li, C.; Yang, W.; Ma, Q.; Jiang, Z.; Li, M.; Lian, X.; Jiao, W.; Wang, L.; et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021, 21, 1645–1653. [CrossRef]
5. Xia, S.; Zhang, Y.; Wang, Y.; Wang, H.; Yang, Y.; Gao, G.F.; Tan, W.; Wu, G.; Xu, M.; Lou, Z.; et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: A randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect. Dis. 2022, 22, 196–208. [CrossRef]
6. Walter, E.B.; Talaat, K.R.; Sabharwal, C.; Gurtman, A.; Lockhart, S.; Paulsen, G.C.; Barnett, E.D.; Muñoz, F.M.; Maldonado, Y.; Pahud, B.A.; et al. Evaluation of the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age. N. Engl. J. Med. 2022, 386, 35–46. [CrossRef] [PubMed]
7. Schaffer DeRoo, S.; Pudalov, N.J.; Fu, L.Y. Planning for a COVID-19 Vaccination Program. JAMA 2020, 323, 2458–2459. [CrossRef] [PubMed]
8. MacDonald, N.E. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015, 33, 4161–4164. [CrossRef] [PubMed]
9. Trent, M.J.; Salmon, D.A.; Machntyre, C.R. Using the health belief model to identify barriers to seasonal influenza vaccination among Australian adults in 2019. Influenza Other Respir Viruses 2021, 15, 678–687. [CrossRef]
10. Coe, A.B.; Gatewood, S.B.; Moczrygamba, L.R.; Goode, J.V.; Beckner, J.O. The use of the health belief model to assess predictors of intent to receive the novel (2009) H1N1 influenza vaccine. Innov. Pharm. 2012, 3, 1–11. [CrossRef]
11. Kang, G.J.; Culp, R.K.; Abbas, K.M. Facilitators and barriers of parental attitudes and beliefs toward school-located influenza vaccination in the United States: Systematic review. Vaccine 2017, 35, 1987–1995. [CrossRef] [PubMed]
12. Glanz, K.; Rimer, B.K.; Viswanath, K. Health Behavior and Health Education: Theory, Research, and Practice, 5th ed.; Glanz, K., Rimer, B.K., Viswanath, K., Eds.; Jossey-Bass: San Francisco, CA, USA, 2015.
13. Olson, O.; Berry, C.; Kumar, N. Addressing Parental Vaccine Hesitancy towards Childhood Vaccines in the United States: A Systematic Literature Review of Communication Interventions and Strategies. Vaccines 2020, 8, 590. [CrossRef]
14. Lin, Y.; Hu, Z.; Zhao, Q.; Alias, H.; Danae, M.; Wong, L.P. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl. Trop. Dis. 2020, 14, e0008961. [CrossRef]
15. Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2021, 27, 225–228. [CrossRef] [PubMed]
16. Elliott, L.; Yang, K. Vaccine Acceptance and Hesitancy among College Students in Nevada: A State-Wide Cross-Sectional Study. Vaccines 2022, 10, 105. [CrossRef] [PubMed]
17. Mant, M.; Aslemand, A.; Prine, A.; Jaagumägi Holland, A. University students’ perspectives, planned uptake, and hesitancy regarding the COVID-19 vaccine: A multi-methods study. PLoS ONE 2021, 16, e0255447. [CrossRef] [PubMed]
18. Baccolini, V.; Renzi, E.; Isonne, C.; Migliara, G.; Massimi, A.; De Vito, C.; Marzuillo, C.; Villari, P. COVID-19 Vaccine Hesitancy among Italian University Students: A Cross-Sectional Survey during the First Months of the Vaccination Campaign. Vaccines 2021, 9, 1292. [CrossRef] [PubMed]
19. Middelman, A.B.; Klein, J.; Quinn, J. Vaccine Hesitancy in the Time of COVID-19: Attitudes and Intentions of Teens and Parents Regarding the COVID-19 Vaccine. Vaccines 2020, 10, 4. [CrossRef] [PubMed]
20. Brandt, E.J.; Rosenberg, J.; Waselewski, M.E.; Amaro, X.; Wasag, J.; Chang, T. National Study of Youth Opinions on Vaccination for COVID-19 in the U.S. J. Adolesc. Health 2021, 68, 869–872. [CrossRef]
21. Wong, W.H.S.; Leung, D.; Chua, G.T.; Duque, J.S.R.; Peare, S.; So, H.K.; Chan, S.M.; Kwan, M.Y.W.; Ip, P.; Lui, Y.L. Adolescents’ attitudes to the COVID-19 vaccination. Vaccine 2022, 40, 967–969. [CrossRef] [PubMed]
22. Xu, Y.; Xu, D.; Luo, L.; Ma, F.; Wang, P.; Li, H.; Li, Q.; Wei, L.; Diao, J.; Liu, Y.; et al. A Cross-Sectional Survey on COVID-19 Vaccine Hesitancy among Parents from Shandong vs. Zhejiang. Front. Public Health 2021, 9, 779720. [CrossRef] [PubMed]
23. Shackman, G. Sample Size and Design Effect. Available online: https://www.alnap.org/help-library/sample-size-and-design-effect (accessed on 24 March 2021).

24. Zhang, M.; Peng, Z.; Zheng, J.; Tan, Y.; Wang, X.; Qin, Y.; Feng, L. Disease burden of influenza in children and current status of vaccine usage in China. Chin. J. Appl. Clin. Pedia. 2019, 34, 91–97. [CrossRef]

25. Vallée-Tourangeau, G.; Promberger, M.; Moon, K.; Wheelock, A.; Sirota, M.; Norton, C.; Sevdalis, N. Motors of influenza vaccination uptake and vaccine advocacy in healthcare workers: Development and validation of two short scales. Vaccine 2018, 36, 6540–6545. [CrossRef] [PubMed]

26. Alhalaseh, L.; Fayoumi, H.; Khalil, B. The Health Belief Model in predicting healthcare workers’ intention for influenza vaccine uptake in Jordan. Vaccine 2020, 38, 7372–7378. [CrossRef] [PubMed]

27. Qiu, Q.; Huang, B.; Zhang, J.; Zhang, J.; Chen, X.; Zhang, H.; Hao, Y.; Li, Z.; Chen, X.; Dong, X. Development, reliability, and validity assessment of a Chinese version of the Parent Attitudes about Childhood Vaccines scale. Chin. J. Vaccines Immun. 2020, 26, 568–573.

28. Shahnaz, H.; Ahmadi-Livani, M.; Pahlavanazadeh, B.; Rajabi, A.; Hamrah, M.S.; Charkazi, A. Assessing preventive health behaviors from COVID-19: A cross sectional study with health belief model in Golestan Province, Northern of Iran. Infect. Dis. Poverty 2020, 9, 157. [CrossRef] [PubMed]

29. Fazel, M.; Puntis, S.; White, S.R.; Townsend, A.; Mansfield, K.L.; Viner, R.; Herring, J.; Pollard, A.J.; Freeman, D. Willingness of children and adolescents to have a COVID-19 vaccination: Results of a large whole schools survey in England. EClinicalMedicine 2021, 40, 101144. [CrossRef] [PubMed]

30. Nilsson, S.; Mattson, J.; Berghammer, M.; Brorsson, A.; Forsner, M.; Jenholt Nolbris, M.; Kull, I.; Lindholm Olander, A.; Ragnarsson, S.; Rullander, A.; et al. To be or not to be vaccinated against COVID-19—The adolescents’ perspective—A mixed-methods study in Sweden. Vaccine X 2021, 9, 100117. [CrossRef] [PubMed]

31. Afifi, T.O.; Salmon, S.; Taillieu, T.; Stewart-Tufescu, A.; Fortier, J.; Driedger, S.M. Older adolescents and young adults willingness to receive the COVID-19 vaccine: Implications for informing public health strategies. Vaccine 2021, 39, 3473–3479. [CrossRef]

32. Murphy, J.; Vallières, F.; Bentall, R.P.; Shevlin, M.; McBride, O.; Hartman, T.K.; McKay, R.; Bennett, K.; Mason, L.; Gibson-Miller, J.; et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat. Commun. 2021, 12, 29. [CrossRef]

33. Schwarzinger, M.; Watson, V.; Arwidsdon, P.; Alla, F.; Luchini, S. COVID-19 vaccine hesitancy in a representative working-age population in France: A survey experiment based on vaccine characteristics. Lancet Public Health 2021, 6, e210–e221. [CrossRef]

34. Nguyen, K.H.; Srivastav, A.; Razzaghi, H.; Williams, W.; Lindley, M.C.; Jorgensen, C.; Abad, N.; Singleton, J.A. COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination—United States, September and December 2020. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 217–222. [CrossRef] [PubMed]

35. Olsusany, O.A.; Bednarczyk, R.A.; Davis, R.L.; Shaban-Nejad, A. Addressing Parental Vaccine Hesitancy and Other Barriers to Childhood/Adolescent Vaccination Uptake during the Coronavirus (COVID-19) Pandemic. Front. Immunol. 2021, 12, 663074. [CrossRef] [PubMed]

36. Zhao, C.; Shi, J.; Zhang, G.; Liu, B. Willingness and associated factors of novel coronavirus vaccination among parents of primary and middle school students in Tongzhou District of Beijing. Chin. J. Sch. Health 2021, 42, 371–374. [CrossRef]

37. Wang, Z.W.; Li, Z.; Huang, H.M.; Yang, Z.C.; Lv, J.; C. Investigation on residents’ awareness of COVID-19 vaccines and vaccination willingness in Guangzhou. Mod. Prev. Med. 2021, 48, 732–737.

38. Behrouzi, B.; Araujo Campoverde, M.V.; Liang, K.; Talbot, H.K.; Bogoch, I.I.; McGeer, A.; Frobert, O.; Loeb, M.; Vardeny, O.; Solomon, S.D.; et al. Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients with COVID-19: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020, 76, 1777–1794. [CrossRef] [PubMed]

39. Fisher, K.A.; Bloomstone, S.J.; Walder, J.; Crawford, S.; Fouayzi, H.; Mazor, K.M. Attitudes toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults. Ann. Intern. Med. 2020, 173, 964–973. [CrossRef]

40. Wang, J.; Jing, R.; Lai, X.; Zhang, H.; Lyu, Y.; Knoll, M.D.; Fang, H. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. Vaccines 2020, 8, 482. [CrossRef] [PubMed]

41. Xu, J.H.; Li, C.P.; Liu, Z.S.; Liu, S.J.; Zhang, D.W.; Ning, X.M.; Xie, D.J. Breeding and planting techniques of the high-quality and high-yield new variety Xinluzao 50. China Cotton 2011, 38, 37.

42. Dror, A.A.; Eisenbach, N.; Taiber, S.; Morozov, N.G.; Mizrachi, M.; Zigron, A.; Srouji, S.; Sela, E. Vaccine hesitancy: The next challenge in the fight against COVID-19. Eur. J. Epidemiol. 2020, 35, 775–779. [CrossRef] [PubMed]

43. Lane, S.; MacDonald, N.E.; Marti, M.; Dumolard, L. Vaccine hesitancy around the globe: Analysis of three years of WHO/UNICEF Joint Reporting Form data-2015-2017. Vaccine 2018, 36, 3861–3867. [CrossRef] [PubMed]

44. Opel, D.J.; Diekema, D.S.; Ross, L.F. Should We Mandate a COVID-19 Vaccine for Children? JAMA Pediatr. 2021, 175, 125–126. [CrossRef] [PubMed]

45. Kaplan, R.M.; Milstein, A. Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance. Proc. Natl. Acad. Sci. USA 2021, 118, e021726118. [CrossRef] [PubMed]

46. Gostin, L.O.; Salmon, D.A. The Dual Epidemics of COVID-19 and Influenza: Vaccine Acceptance, Coverage, and Mandates. JAMA 2020, 324, 335–336. [CrossRef] [PubMed]

47. Chen, W.; Chen, Z.; Xiang, Y.; Deng, C.; Zhang, H.; Wang, J. Simultaneous influence of sympathetic autonomic stress on Schlemm’s canal, intraocular pressure and ocular circulation. Sci. Rep. 2019, 9, 20060. [CrossRef] [PubMed]
48. Li, D.; Lin, E.Z.; Brault, M.A.; Paquette, J.; Vermund, S.H.; Godri Pollitt, K.J. Reopening Schools after a Novel Coronavirus Surge. *Adv. Exp. Med. Biol.* 2021, 1318, 785–813. [CrossRef] [PubMed]

49. Vermund, S.H.; Pitzer, V.E. Asymptomatic Transmission and the Infection Fatality Risk for COVID-19: Implications for School Reopening. *Clin. Infect. Dis.* 2021, 72, 1493–1496. [CrossRef] [PubMed]